Molecular Tumor Board

• Jill Kolesar, PharmD, MS, Co-Director
• Rachel Miller, MD, Co-Director

Molecular Tumor Board Office Phone: 1-844-622-0341

Click here to contact the tumor board by email, or email Dr. Kolesar directly.

---

Administrative Office

Abigail Anderson, PhD, aman239@uky.edu
MTB Project Manager

Rebecca Carpenter, rebecca.carpenter@uky.edu
Administrative Support Associate

The Molecular Tumor Board (MTB) meets:

• 12 p.m.
• Every first and third Tuesday

MTB meetings are currently held via Zoom. Please email either Abigail Anderson, PhD or Rebecca Carpenter for Zoom details to attend.

Some MTB meetings will include a 15-minute informational update on Precision Medicine. See Schedule for Topics and Speakers.

To schedule a case presentation, review the details in the Case Submission section. All cases must be submitted to MTB seven days prior to meeting date.

MTB Meeting Schedule

Molecular Tumor Board 2021
Month	Day / Tues	Location
January	5	Zoom
January	19	Zoom
February	2	Zoom
February	16	Zoom
March	2	Zoom
March	16	Zoom
April	6	Zoom
April	20	Zoom
May	4	Zoom
May	18	Zoom
June	1	Zoom
June	15	Zoom
July	6	Zoom
July	20	Zoom
August	3	Zoom
August	17	Zoom
September CANCELLED	7	Zoom
September	21	Zoom
October	5	Zoom
October	19	Zoom
November	2	Zoom
November	16	Zoom
December	7	Zoom
December	21	Zoom

Continuing Medical Education (CME)

If clinicians or pharmacists want to obtain CE Credit for this meeting, they must attend the meeting in person or via teleconference, then enter the provided access code on the CE Central website. Any questions or concerns regarding CE Credit can be directed to the MTB Manager at mtb@uky.edu.  

Policy on Disclosure

It is the policy of the Markey Cancer Center that the faculty, authors, planners and other persons who may influence the content of this CME activity disclose all relevant financial relationships with commercial interests in order to allow CME staff to identify and resolve any potential conflicts of interest. Faculty must also disclose any planned discussions of unlabeled/unapproved uses of drugs or devices during their presentation.

Cases must be submitted at least seven days prior to the meeting date.

Genomics reports from UK HealthCare or external sources (Foundation, MATCH, etc.) can be submitted.

A patient's genomic report is required for case submission. Please see how to order a genomic report through UK HealthCare under Order a Genomic Report below. 

If you already have a genomic report, fill out the case submission form online, or download the form here.

The patient’s genomic report can be sent to MTB by email.

When the case submission and genomic report are received, the MTB manager will schedule the case for presentation and invite the treating clinician to the meeting.

Treatment recommendations will be discussed at the MTB meeting. Recommendation letters will be faxed and/or mailed or uploaded into the electronic health record per the preference of the submitting physician. Specify method of results reporting on the case submission form.

Note: There is no cost to submit a case to the Markey Cancer Center Molecular Tumor Board.

Genomic reports can be ordered through the Clinical Molecular and Genomic Pathology department. There is a comprehensive solid tumor panel, some gene-specific hematological panels as well as a larger hematological malignancy panel. Please see the information forms below on the methodology of the panels and what genes are included in the panels. 

To order a genomic report, the clinical staff must:

1. Fill out the Requisition Form.
2. Send tissue blocks to the address listed on the form: 800 Rose St. HA619, Lexington, KY 40536-0293

If you have any questions about ordering a genomic panel for your patient, please contact the Clinical Molecular and Genomic Pathology department at (859) 323-5327 or cmgp@uky.edu.

• Download the Solid Tumor Test Requisition Form (PDF, 47 KB)
• Download the Hematologic Malignancy Test Requisition Form (PDF, 80 KB)
• Download the Lung Nodule Review Board flyer (PDF, 74 KB)
  and submit your referral form online

Solid tumor panels:

Comprehensive Solid Tumor Panel (198 Genes) (PDF, 119 KB)

Hematologic Malignancy Panels:

FLT3-ITD and FLT3-TKD (PDF, 18 KB)

NPM1 (PDF, 141 KB)

CEBPA (PDF, 150 KB)

Hematologic Malignancy Panel (94 Genes) (PDF, 115 KB)

The Molecular Tumor Board currently has two prospective clinical trials evaluating integration of Precision Medicine into cancer therapeutics.

• Part 1:  A prospective observational cohort study evaluating outcomes of genomic testing in patients with poor prognosis cancer.
• Part 2: A therapeutic phase 2 sub-study evaluating genomic testing in human cancer and outcomes of targeted therapies recommended by an institutional multidisciplinary molecular tumor board in patients with poor prognosis cancer.

Researchers who are interested in using the data or specimen collected under these protocols must complete the data request form.

Guidance documents are used to establish guidelines for Molecular Tumor Board (MTB) recommendations for advanced cancer.

MTB guidance documents will be made available to download below.

Download Guidance MTB Documents

• Guidance Document: Off-Label Use (PDF, 114.17 KB)
• UK Molecular Tumor Genetic Testing Guideline (PDF, 184 KB)

Reference documents are used to aid Molecular Tumor Board members in meeting discussions and advanced care recommendations.

MTB reference documents will be made available for download below on this page.

Download Reference MTB Documents

• Ovarian Cancer: When to Test and Emerging Therapies - Precision Medicine Symposium 2018 (PDF, 3 MB)
• BAP1 Presentation - MTB Meeting, March 7, 2017 (PDF)
• Navigating from Somatic Tumor Testing to Germline Genetic Testing – MTB Meeting, March 21, 2017 (PDF)
• Therapeutic targeting & patient selection for cancers with homologous recombination defects – MTB Journal Club, Sept. 5, 2017

Watch MTB presentations

• Clinical Update on Breast Cancer: When to Test and Emerging Therapies
• Clinical Update on GI Cancer: When to Test and Emerging Therapies
• Clinical Update on Lung Cancer: When to Test and Emerging Therapies
• Next Generation Sequencing: What They Are & When to Order Them
• Intro to MCC Clinical Practice Guidelines

Directors	Site Leaders
Jill Kolesar, PharmD Professor, College of Pharmacy Department of Pharmacy Practice and Science	Chandler Park, MD, FACP Research Medical Director at Hardin Memorial Hospital, Central Kentucky Region UK Markey Cancer Center Research Network
Rachel Ware Miller, MD Associate Professor, Division of Gynecologic Oncology Department of Obstetrics and Gynecology
Administrative Office
Abigail Anderson, PhD, MTB Project Manager aman239@uky.edu Rebecca Carpenter, Administrative Support Associate rebecca.carpenter@uky.edu